Patient Care
Better patient care through less invasive surveillance.
Uromonitor® supports a more patient-centred bladder cancer surveillance pathway by adding molecular urine testing that may reduce unnecessary invasive procedures and provide faster reassurance where clinically appropriate.
Surveillance should be clinically safe, but less burdensome where possible.
Many bladder cancer patients require repeated follow-up over years. Cystoscopy remains important, but repeated invasive procedures can be uncomfortable, inconvenient and anxiety-provoking. Uromonitor gives clinicians another way to gather useful molecular information from a urine sample.
Less invasive surveillance
A urine-based molecular test can reduce the need for immediate cystoscopy in selected patients where the clinical pathway supports that decision.
Fewer unnecessary appointments
Same-sample or urine-first workflows may reduce repeat visits, additional sampling and avoidable hospital attendance.
Better long-term experience
Because surveillance can continue for years, reducing unnecessary procedural burden can make a meaningful difference to patient experience.
A more modern follow-up experience.
The aim is not to remove clinical review. The aim is to make surveillance more intelligent, less invasive and more personalised for appropriate patients.
Clinical review
The clinician considers history, recurrence risk and previous results.
Urine sample
The patient provides a non-invasive sample for molecular testing.
Result interpretation
The result is reviewed alongside clinical risk and cytology where relevant.
Reassurance or escalation
Negative results may support reassurance; positive results can support escalation.
Personalised follow-up
The follow-up plan remains clinician-led and risk-adapted.
Better patient care means reducing avoidable burden.
A molecular urine test can support a calmer, less invasive surveillance experience for suitable patients, while preserving the role of cystoscopy and clinical judgement where investigation is needed.
Patient care improves when the pathway stays governed.
Uromonitor should not be positioned as a direct-to-consumer screening test or a blanket replacement for cystoscopy. Its value is strongest when used inside a clinician-led bladder cancer surveillance pathway.
Discuss patient-centred surveillance.
Speak to Progen Diagnostics about how Uromonitor could support less invasive, risk-adapted bladder cancer surveillance while keeping clinical judgement at the centre of care.